Furthermore, the risk for developing a CVT is higher in patients with hypercoagulable states such as hyperhomocysteinemia, protein C, protein S and antithrombin III deficiencies, as well as careers of prothrombin gene and factor V Leiden (FVL) mutation.1,2 Accordingly, the prothrombotic screening for hypercoagulable states due to genetic and acquired disorders is an important part of investigating the etiology of CVT.1,2. This evidence concerns the gene F5 and thrombophilia.